New Three-Drug cocktail aims to beat aggressive leukemia
NCT ID NCT07605949
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study tests a new combination of three drugs—revumenib, azacitidine, and venetoclax—in people newly diagnosed with a specific, hard-to-treat leukemia called KMT2A-rearranged AML. The goal is to see if this cocktail can help more patients achieve remission with fewer side effects. The trial will enroll 88 adults and includes a phase where some patients may continue treatment after a stem cell transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- revumenib, azacitidine, and venetoclax
- What this could lead to
- If successful, this combination could offer a more effective and less toxic first treatment for people with this aggressive leukemia, potentially leading to better remission rates and survival.
- What could go wrong
- This is a Phase 2 trial with only 88 participants, so results are preliminary. The drug combination may cause significant side effects, and not all patients may respond. It is not yet proven to be better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KMT2A-REARRANGED ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599-7295, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill turn the tide against a bone marrow disorder?
- Can a targeted pill boost standard therapy for hard-to-treat leukemia?
- Can an app help older leukemia patients track their health at home?
- New cell therapy aims to supercharge Kids' immune cells after transplant
- New hope for tough blood cancers: experimental drug MGD024 enters human testing